Magnetic drug targeting reduces the chemotherapeutic burden on circulating leukocytes

International Journal of Molecular Sciences

Volumn 14, Issue 4, 2013, Pages 7341-7355

  Janko, Christina ^a,b   Dürr, Stephan ^b   Munoz, Luis E ^a   Lyer, Stefan ^b   Chaurio, Ricardo ^a   Tietze, Rainer ^b   von Löhneysen, Sarah ^a   Schorn, Christine ^a   Herrmann, Martin ^a   Alexiou, Christoph ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Chemotherapy; Immune system; Iron oxide nanoparticles; Leukocytes; Magnetic drug targeting; Mitoxantrone

Indexed keywords

MITOXANTRONE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; CYTOTOXIN; MAGNETITE NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LEUKOCYTE; LYMPHOCYTE; MAGNETIC DRUG TARGETING; MONOCYTE; NEOPLASM; NONHUMAN; RABBIT; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; HUMAN; JURKAT CELL LINE; MAGNETIC FIELD; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PROCEDURES;

ANIMALS; CELL PROLIFERATION; CYTOTOXINS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; JURKAT CELLS; LEUKOCYTES; MAGNETIC FIELDS; MAGNETITE NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; RABBITS;

EID: 84876011818     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14047341     Document Type: Article

References (31)

1. Shimizu, K.; Oku, N. Cancer anti-angiogenic therapy. Biol. Pharm. Bull. 2004, 27, 599-605.
2. Tietze, R.; Lyer, S.; Durr, S.; Alexiou, C. Nanoparticles for cancer therapy using magnetic forces. Nanomedicine (London, England) 2012, 7, 447-457.
3. Durr, S.; Tietze, R.; Lyer, S.; Alexiou, C. Nanomedicine in otorhinolaryngology-Future prospects. Laryngorhinootologie 2012, 91, 6-12.
4. Alexiou, C.; Tietze, R.; Schreiber, E.; Lyer, S. Nanomedicine: Magnetic nanoparticles for drug delivery and hyperthermia-new chances for cancer therapy. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010, 53, 839-845.
5. Alexiou, C.; Jurgons, R.; Schmid, R.; Erhardt, W.; Parak, F.; Bergemann, C.; Iro, H. Magnetic drug targeting-a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies. HNO 2005, 53, 618-622.
6. Alexiou, C.; Arnold, W.; Klein, R.J.; Parak, F.G.; Hulin, P.; Bergemann, C.; Erhardt, W.; Wagenpfeil, S.; Lubbe, A.S. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000, 60, 6641-6648.
7. Fox, M.E.; Smith, P.J. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res. 1990, 50, 5813-5818.
8. Ballestrero, A.; Ferrando, F.; Garuti, A.; Basta, P.; Gonella, R.; Esposito, M.; Vannozzi, M.O.; Sorice, G.; Friedman, D.; Puglisi, M.; et al. High-dose mitoxantrone with peripheral blood progenitor cell rescue: Toxicity, pharmacokinetics and implications for dosage and schedule. Br. J. Cancer 1997, 76, 797-804.
9. Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991-998.
10. Scott, A.M.; Wolchok, J.D.; Old, L.J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12, 278-287.
11. Palucka, K.; Ueno, H.; Banchereau, J. Recent developments in cancer vaccines. J. Immunol. 2011, 186, 1325-1331.
12. Frey, B.; Rubner, Y.; Wunderlich, R.; Weiss, E.M.; Pockley, A.G.; Fietkau, R.; Gaipl, U.S. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation-implications for cancer therapies. Curr. Med. Chem. 2012, 19, 1751-1764.
13. Kapuscinski, J.; Darzynkiewicz, Z.; Traganos, F.; Melamed, M.R. Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedion e, with nucleic acids. Biochem. Pharmacol. 1981, 30, 231-240.
14. Frank, P.; Novak, R.F. Mitoxantrone and bisantrene inhibition of platelet aggregation and prostaglandin E2 production in vitro. Biochem. Pharmacol. 1985, 34, 3609-3614.
15. Khalafalla, S.E.; Reimers, G.W. Preparation of dilution-stable aqueous magnetic fluids. IEEE Trans. Magn. 1980, 16, 178-183.
16. Tietze, R.; Schreiber, E.; Lyer, S.; Alexiou, C. Mitoxantrone loaded superparamagnetic nanoparticles for drug targeting: A versatile and sensitive method for quantification of drug enrichment in rabbit tissues using HPLC-UV. J. Biomed. Biotechnol. 2010, 597304:1-597304:8.
17. Alexiou, C.; Diehl, D.; Henninger, P.; Iro, H.; Rockelein, R.; Schmidt, W.; Weber, H. A high field gradient magnet for magnetic drug targeting. IEEE Trans Appl. Supercon. 2006, 16, 1527-1530.
18. Elstein, K.H.; Zucker, R.M. Comparison of cellular and nuclear flow cytometric techniques for discriminating apoptotic subpopulations. Exp. Cell Res. 1994, 211, 322-331.
19. Hagenhofer, M.; Germaier, H.; Hohenadl, C.; Rohwer, P.; Kalden, J.R.; Herrmann, M. UV-B irradiated cell lines execute programmed cell death in various forms. Apoptosis 1998, 3, 123-132.
20. Vermes, I.; Haanen, C.; Steffens-Nakken, H.; Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 1995, 184, 39-51.
21. Smith, P.J.; Sykes, H.R.; Fox, M.E.; Furlong, I.J. Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage. Cancer Res. 1992, 52, 4000-4008.
22. Chan, A.; Weilbach, F.X.; Toyka, K.V.; Gold, R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin. Exp. Immunol. 2005, 139, 152-158.
23. Durr, S.; Lyer, S.; Mann, J.; Janko, C.; Tietze, R.; Schreiber, E.; Herrmann, M.; Alexiou, C. Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles. Anticancer Res. 2012, 32, 1983-1989.
24. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C.; Criollo, A.; Mignot, G.; Maiuri, M.C.; Ullrich, E.; Saulnier, P.; et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13, 1050-1059.
25. Zitvogel, L.; Apetoh, L.; Ghiringhelli, F.; Andre, F.; Tesniere, A.; Kroemer, G. The anticancer immune response: Indispensable for therapeutic success? J. Clin. Invest. 2008, 118, 1991-2001.
26. Apetoh, L.; Mignot, G.; Panaretakis, T.; Kroemer, G.; Zitvogel, L. Immunogenicity of anthracyclines: Moving towards more personalized medicine. Trends Mol. Med. 2008, 14, 141-151.
27. Galluzzi, L.; Senovilla, L.; Zitvogel, L.; Kroemer, G. The secret ally: Immunostimulation by anticancer drugs. Nat. Rev. Drug Discov. 2012, 11, 215-233.
28. Cao, C.; Han, Y.; Ren, Y.; Wang, Y. Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response. Cell Mol. Immunol. 2009, 6, 469-475.
29. Zolnik, B.S.; Gonzalez-Fernandez, A.; Sadrieh, N.; Dobrovolskaia, M.A. Nanoparticles and the immune system. Endocrinology 2010, 151, 458-465.
30. Ogunwale, B.; Schmidt-Ott, A.; Meek, R.M.; Brewer, J.M. Investigating the immunologic effects of CoCr nanoparticles. Clin. Orthop. Relat. Res. 2009, 467, 3010-3016.
31. Chen, B.A.; Jin, N.; Wang, J.; Ding, J.; Gao, C.; Cheng, J.; Xia, G.; Gao, F.; Zhou, Y.; Chen, Y.; et al. The effect of magnetic nanoparticles of Fe3O4 on immune function in normal ICR mice. Int. J. Nanomed. 2010, 5, 593-599.